Clinical significance of radiation-induced CD133 expression in residual rectal cancer cells after chemoradiotherapy

Experimental and Therapeutic Medicine

Volumn 3, Issue 3, 2012, Pages 403-409

  Kawamoto, Aya ^a   Tanaka, Koji ^a   Saigusa, Susumu ^a   Toiyama, Yuji ^a   Morimoto, Yuhki ^a   Fujikawa, Hiroyuki ^a   Iwata, Takashi ^a   Matsushita, Kohei ^a   Yokoe, Takeshi ^a   Yasuda, Hiromi ^a   Inoue, Yasuhiro ^a   Miki, Chikao ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CD133; CD44; Chemoradiotherapy; Rectal cancer

Indexed keywords

CD133 ANTIGEN; FLUOROURACIL; HERMES ANTIGEN; UFT;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CELL SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IRRADIATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84862954837     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.438     Document Type: Article

References (19)

1. Eyler CE and Rich JN: Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26: 2839-2845, 2008.
2. Baumann M, Krause M and Hill R: Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8: 545-554, 2008.
3. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006.
4. Tsuchida R, Das B, Yeger H, et al: Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. Oncogene 27: 3923-3934, 2006.
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and de Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
6. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
7. + population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 15: 2927-2933, 2008.
8. Du L, Wang H, He L, et al: CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14: 6751-6760, 2008.
9. Chu P, Clanton DJ, Snipas TS, et al: Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 124: 1312-1321, 2009.
10. Yoshikawa R, Kusunoki M, Yanagi H, et al: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61: 1029-1037, 2001.
11. Sobin LH and Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80: 1803-1804, 1997.
12. Dworak O, Keilholz L and Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12: 19-23, 1997.
13. Bijwa a rd K E, Ag ui lera NS, Moncza k Y, Tr udel M, Taubenberger JK and Lichy JH: Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem 47: 195-201, 2001.
14. Liu R, Wang X, Chen GY, et al: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217-226, 2007.
15. Zeppernick F, Ahmadi R, Campos B, et al: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: 123-129, 2008.
16. Horst D, Kriegl L, Engel J, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 99: 1285-1289, 2008.
17. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N and Ochiai A: Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 99: 1578-1583, 2008.
18. Bosset JF, Collette L, Calais G, et al; EORTC Radiotherapy Group Trial 22921: Chemotherapy with preoperative radio-therapy in rectal cancer. N Engl J Med 355: 1114-1123, 2007.
19. Bujko K, Michalski W, Kepka L, et al; Polish Colorectal Study Group: Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 67: 369-377, 2007.